|Mr. Christophe Weber||Pres, CEO & Representative Director||11.69M||N/A||1966|
|Mr. Constantine Saroukos||CFO & Representative Director||4.22M||N/A||1971|
|Mr. Yasuhiko Yamanaka||Advisor||297.2k||N/A||1956|
|Dr. Andrew S. Plump||Pres of R&D and Representative Director||6.01M||N/A||1965|
|Dr. Seigo Izumo||Chair of Management Board||N/A||N/A||N/A|
|Mr. Haruhiko Hirate||Member of Management Board||N/A||N/A||1957|
|Salvatore Alesci||Member of Management Board and Head of R&D Global Science & Biomedical Policy||N/A||N/A||N/A|
|Norimasa Takeda||Chief Accounting Officer & Corp. Controller||N/A||N/A||N/A|
|Mr. Iwaaki Taniguchi||Sr. VP of Corp. Fin. & Controlling Department||N/A||N/A||N/A|
|Mr. Gabriele Ricci||Chief Data & Technology Officer||N/A||N/A||N/A|
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Takeda Pharmaceutical Company Limited’s ISS governance QualityScore as of 1 May 2022 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 9; Compensation: 1.